SCHEMBL4864387

SCHEMBL4864387

Cc1nnc(-c2ccc(C)c(-c3ccccc3C(=O)NCc3ccc(Cl)cc3)c2)o1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 12/20 0.74
MAPK11 Q15759 2/20 0.54
ALDH1A1 P00352 2/20 0.48
HPGD P15428 2/20 0.48
KDM4E B2RXH2 1/20 0.48
POLB P06746 1/20 0.48
MAPT P10636 1/20 0.48
HTT P42858 1/20 0.48
CHRM1 P11229 1/20 0.46
HAT1 O14929 2/20 0.46
EP300 Q09472 2/20 0.46
TSHR P16473 2/20 0.44
LMNA P02545 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
HSD17B10 Q99714 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
MEN1 O00255 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Gw708893X SCHEMBL4856407 0.85 MAPK14 (1.00) MAPK14MAPK11LCKCSF1R
SCHEMBL4863522 0.79 MAPK14 (1.00) MAPK14MAPK11
SCHEMBL5657829 0.79 MAPK14 (0.57) MAPK14MAPK11ALDH1A1HPGDTSHR
SCHEMBL4859805 0.77 MAPK14 (0.80) MAPK14MAPK11
SCHEMBL6605534 0.77 MAPK14 (0.80) MAPK14MAPK11
SCHEMBL4855124 0.77 MAPK14 (0.85) MAPK14MAPK11
SCHEMBL4861805 0.77 MAPK14 (0.57) MAPK14MAPK11ALDH1A1HPGDKDM4E
SCHEMBL4858295 0.76 MAPK14 (0.83) MAPK14MAPK11
SCHEMBL4856613 0.76 MAPK14 (0.83) MAPK14MAPK11
SCHEMBL4860491 0.76 MAPK14 (0.84) MAPK14MAPK11HPGDHTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7384963-B2 2′-Methyl-5-(1,3,4-oxadiazol-2-yl)1, 1′-biphenyl-4-carboxaide derivatives and their use as p38 kinase GLAXO GROUP LIMITED (GB) 2008-06-10 US disclosed
US-20040266839-A1 2'-Methyl-5-(1,3,4-oxadiazol-2-yl)1,1'-biphenyl-4-carboxaide derivatives and their use as p38 kinase inhibitors GLAXO GROUP LIMITED (GB) 2004-12-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040266839-A1 2'-Methyl-5-(1,3,4-oxadiazol-2-yl)1,1'-biphenyl-4-carboxaide derivatives and their use as p38 kinase inhibitors MAPK1, MAPK3, MAPK6 MAPK14 11/4885MAPK11 17/4885ALDH1A1 1805/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.